The Medicare Access and CHIP Reauthorization Act (MACRA) is the biggest change to how Medicare pays for services in decades. It will accelerate the movement towards value-based payments—where what health care providers get paid depends, at least partially, on the quality of care they provide, not just the volume of services. On June 27, Families USA submitted comments about how the law will be implemented.
As drug prices continue to rise at an unsustainable rate, we must ensure that our health care system and its financial incentives enhance the quality and value of care. We believe the Medicare Part B prescription drug model proposed by the Centers for Medicare & Medicaid Services (CMS) creates value for the patient and the program by encouraging treatment choices that have been shown to improve care and health outcomes.
Last Wednesday, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule to implement key provisions of the Medicare Access & CHIP Reauthorization Act. Passed with bipartisan support in 2015, MACRA represents is an important opportunity to improve the quality of care delivered through Medicare. Given the number of people who are enrolled in Medicare and the number of providers who see Medicare patients, these changes will have a significant impact throughout the entire health care system.